MTOR and colorectal carcinoma: In contrast, RPTOR, an oncogenic component of the PI3K–mTOR pathway, exhibited a higher mutation frequency in Korean CRC (13%) compared with TCGA‐CRC (1%), suggesting potential cohort‐specific activation of this signaling axis.